Press Release Oct 04 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release regarding its tentative approval from the USFDA for Amantadine Extended-Release Capsules. The approval allows Zydus Pharmaceuticals (USA) Inc. to market the capsules, which are used to treat dyskinesia in Parkinson's disease patients. The drug will be manufactured at Zydus's facility in Ahmedabad, India, and had annual sales of a specific amount in the United States.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Oct 03 2022
- Press Release Oct 01 2022
- Press Release Sep 20 2022
- Press Release Sep 16 2022
- Press Release Sep 13 2022
Later from Zydus Lifesciences
- Press Release Oct 06 2022
- Zydus Lifesciences: General updates
- Press Release Oct 17 2022
- Press Release Oct 22 2022
- Press Release Oct 26 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences